SK Biopharmaceuticals Broadens Radiopharmaceutical Therapy Portfolio with New Licensing Agreement SK Biopharmaceuticals announces the acquisition of WT-7695, enhancing its radiopharmaceutical therapy portfolio through a global agreement aimed at tackling cancer treatments.

SK Biopharmaceuticals Broadens Radiopharmaceutical Therapy Portfolio with New Licensing Agreement #South_Korea #Seoul #radiopharmaceuticals #SK_Biopharmaceuticals #WT-7695

SK Biopharmaceuticals Partners with Eurofarma for AI-Driven Epilepsy Care Solution SK Biopharmaceuticals and Eurofarma establish Mentis Care to enhance epilepsy management through innovative AI technology in healthcare.

SK Biopharmaceuticals Partners with Eurofarma for AI-Driven Epilepsy Care Solution #South_Korea #Seoul #SK_Biopharmaceuticals #Eurofarma #Mentis_Care

Breakthrough Findings from SK Life Science Labs on Cancer Inhibitors Presented at AACR 2025 SK Life Science Labs unveiled transformative findings at the AACR Annual Meeting, demonstrating the effectiveness of p300-selective degraders in cancer treatment.

Breakthrough Findings from SK Life Science Labs on Cancer Inhibitors Presented at AACR 2025 #United_States #Cancer_Research #King_of_Prussia #SK_Biopharmaceuticals #p300_degraders

SK Biopharmaceuticals and ProEn Therapeutics Collaborate to Advance Oncology Research and Develop Radiopharmaceuticals SK Biopharmaceuticals partners with ProEn Therapeutics to further oncology research and enhance its pipeline for radiopharmaceutical therapies by 2027.

SK Biopharmaceuticals and ProEn Therapeutics Collaborate to Advance Oncology Research and Develop Radiopharmaceuticals #South_Korea #Seoul #radiopharmaceuticals #SK_Biopharmaceuticals #ProEn_Therapeutics